Nov 30, 2022 / 01:30PM GMT
Jason M. Bednar - Piper Sandler & Co., Research Division - VP & Senior Research Analyst
All right. Good morning, everybody. I'm Jason Bednar. I cover med tech here at Piper. Our next fireside chat is with Masimo. Very happy to have with us today from Masimo, SVP of Finance; Mike Lazinski; and VP of Investor Relations, Eli Kammerman. Thanks a lot for being here, both of you. I really appreciate having you both with us today.
Questions and Answers:
Jason M. Bednar - Piper Sandler & Co., Research Division - VP & Senior Research AnalystSo why don't we just dive right into Q&A. And Eli, Mike, I really like to start around on the messaging around margins coming out of last quarter, if we could. It was a big focal point on the call. It seems like the message was pretty direct on gross margins, continuing into '23 at the level that we're probably exiting '22. I don't know if you want to add any color on top of that or if I misunderstood that. But that's how I interpret it. And then maybe we get some improvement on that gross margin as we get
Trustpilot
